Everything in Moderation?

Premium

The earlier cancer is found, the better the patient's chances for survival, the conventional wisdom goes. But oncologists are now saying that early detection may not be all it's cracked up to be, reports the Associated Press' Lauran Neergaard. Some cancers grow slowly enough that catching them at the later stages is still OK for patients, and some cancers are so aggressive that it almost doesn't matter when they are caught, Neergaard says.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.